As Cage embraces his destiny, a hologram of Iron Lad tells him: “Together, we will free the world.” February 2025: Cage’s prison break is foiled by Gordium guards.

Introduction. Obstructive sleep apnea (OSA) has been associated with clinical impairments, including excessive daytime sleepiness, cardiovascular, metabolic, and cognitive problems, increased risk of ...

Obstructive sleep apnea affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment options REDWOOD CITY, Calif. , June 9, 2025 /PRNewswire/ -- ...

Founded in 2022, Mosanna Therapeutics is a clinical-stage biotech company that is pioneering a novel pharmaceutical approach to treating obstructive sleep apnea (OSA) using an easily administered ...

MONDAY, June 9, 2025 (HealthDay News) -- Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with ...

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body's natural airway reflex.

Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical Trials Biotech veteran David Weber has been appointed CEO to lead the company through clinical ...

REDWOOD CITY, Calif., June 9, 2025 /PRNewswire/ -- Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA), today announced the close of $80 million in Series ...

EQT Life Sciences Leads USD 80 Million Series A Funding Round In Mosanna Therapeutics To Advance Sleep Apnea Nasal Spray. Date. 2025-06-09 11:01:19. Share on Facebook; Tweet on Twitter ...